Anderson Cancer Center. He has received a one-year Pilot Award to study the role of a protein called FoxO in the molecular pathogenesis of LAM. FoxO serves as a transcription factor which can regulate the expression of many gene targets and functions as an important component in PI3K pathway, which is a heavily studied target in current cancer drug development pipelines. Given the critical role of FoxO in PI3K signaling, Dr. Gan hopes to expand drug development opportunities for LAM and/or identify a FoxO biomarker which may provide a pharmacodynamic marker for monitoring the impact of anti-PI3K drugs in LAM clinical trials.